-
Snowboarding monk in spotlight after S. Korea's Olympic glory
-
Bangladesh's Tarique Rahman poised to be PM as Islamists concede
-
What does Greenland's mining industry look like?
-
Greenland prepares next generation for mining future
-
China top court says drivers responsible despite autonomous technology
-
Sixers rookie Edgecombe leads 'Team Vince' to NBA Rising Stars crown
-
Rubio at Munich security meet to address Europeans rattled by Trump
-
Medal-winner Sato says Malinin paid for 'toxic schedule'
-
Carney offers support of united Canada to town devastated by mass shooting
-
All-in on AI: what TikTok creator ByteDance did next
-
Healthy Ohtani has Cy Young Award in sights
-
One of Lima's top beaches to close Sunday over pollution
-
'Nothing is impossible': Shaidorov shocks favourite Malinin to make history
-
Malinin wilts at Olympics as Heraskevych loses ban appeal
-
Bhatia joins Hisatsune in Pebble Beach lead as Fowler surges
-
Malinin meltdown hands Shaidorov Olympic men's figure skating gold
-
Top seed Fritz makes ATP Dallas semis with fantastic finish
-
Patriots star receiver Diggs pleads not guilty to assault charges
-
Havana refinery fire under control as Cuba battles fuel shortages
-
Peru Congress to debate impeachment of interim president on Tuesday
-
Snowboard veteran James targets 2030 Games after Olympic heartbreak
-
Costa Rica digs up mastodon, giant sloth bones in major archaeological find
-
Trump says change of power in Iran would be 'best thing'
-
Paris police shoot dead knife man at Arc de Triomphe
-
Japan's Totsuka wins Olympic halfpipe thriller to deny James elusive gold
-
Canada's PM due in mass shooting town as new details emerge
-
Neto treble fires Chelsea's FA Cup rout of Hull
-
Arbitrator rules NFL union 'report cards' must stay private
-
Dortmund thump Mainz to close in on Bayern
-
WHO sets out concerns over US vaccine trial in G.Bissau
-
Skeleton racer Weston wins Olympic gold for Britain
-
Ex-CNN anchor pleads not guilty to charges from US church protest
-
Berlin premiere for pic on jazz piano legend Bill Evans
-
Fire at refinery in Havana as Cuba battles fuel shortages
-
A Friday night concert in Kyiv to 'warm souls'
-
PSG stunned by rampant Rennes, giving Lens chance to move top
-
Japan's Totsuka wins Olympic halfpipe thriller as James misses out on gold
-
Indian writer Roy pulls out of Berlin Film Festival over Gaza row
-
Conflicts turning on civilians, warns Red Cross chief
-
Europe calls for US reset at security talks
-
Peru leader under investigation for influence peddling
-
Rising star Mboko sets up Qatar Open final against Muchova
-
Canada PM to mourn with grieving town, new details emerge on shooter
-
US waives Venezuela oil sanctions as Trump says expects to visit
-
NBA star Chris Paul retires at age 40 after 21 seasons
-
WTO chief urges China to shift on trade surplus
-
Vonn hoping to return to USA after fourth surgery on broken leg
-
Trump sending second aircraft carrier to pile pressure on Iran
-
Heraskevych loses Olympics disqualification appeal, Malinin eyes second gold
-
Mercedes have 'taken a step back': Russell
Ozempic slimming craze sweeps Kosovo despite side effects
Kosovo influencer Tringa Kadriu sees the slimming drug Ozempic as a chance to shed excess pounds -- and she is not the only one in her Balkan nation, where more than half the population is overweight.
"I want to lose 15-16 kilos (33-35 pounds) in two months," Kadriu, 29, told AFP, "and then I'll continue with fitness".
Ozempic, approved in the United States to treat diabetes in 2017, has found an international market for people trying to lose weight.
Despite its cost, the drug has soared in popularity in Kosovo, a country of 1.7 million.
While Kosovo authorities have not sanctioned the drug's use for weight loss, they have noted their limited means to confront use of a drug widely available in the country.
Merita Emini-Sadiku, who heads the Kosovo university hospital's endocrinology clinic, said the cost of the drug had soared.
"The monthly dose used to be 75-80 euros ($85-91), while now it is 130-140 euros ($147-159), probably due to high demand," she said.
But she warned that "Ozempic has side effects that people are not aware of".
Ozempic use can potentially cause issues including thyroid cancer, pancreatitis, gastroparesis and bowel obstruction, according to the latest studies.
- 'Constant demand' -
Meant to treat Type 2 diabetes -- of which the WHO says Kosovo has lower than average levels -- the drug regulates blood sugar levels but also helps suppress hunger, leading to a lower calorie intake.
As a result, its potentially cancerous complications have done little to stem the drug's popularity or availability.
"I checked a lot of pharmacies in Kosovo and I noticed that Ozempic is very easy to get," said Kadriu, adding that pharmacists even suggested she gradually increase her dosage.
A worker at a pharmacy in the capital Pristina's downtown, who asked to remain anonymous, said she had trouble recalling when someone last came into her pharmacy to buy Ozempic with a diabetes prescription.
"But we have a constant demand for Ozempic without a prescription. You can guess why," she said.
Given its availability, Emini-Sadiku said authorities should exercise greater control over Ozempic's distribution.
But Bujar Vitija, a journalist specialising in health, said that would be tricky to achieve given Kosovo's poor health record-keeping.
"Unfortunately there is no data," Vitija said.
With 1,500 to 1,600 private pharmacies in Kosovo, the country's 20 pharmaceutical inspectors have their work cut out for them, he added.
- Ozempic 'every day' -
While Kosovo has lower levels of obesity than the European average, more than 57 percent of the population is overweight and 20 percent is clinically obese, according to a 2019 World Health Organization report.
And women, who are more likely to face societal pressure to be thin, were 66 percent more likely to be obese than men, the WHO report found.
But not every Kosovar who has used Ozempic had the best experience with the drug.
"I took Ozempic on the advice of a doctor for two years but it had no effect," said 48-year-old merchant Lulzim Rrahmani, adding that three of his relatives even experienced "a negative effect of the drug".
"It was just a waste of money and time."
Given the risk of side effects, Emini-Sadiku said Ozempic was "by no means to be taken without a doctor's prescription".
Yet Kadriu said she would not be deterred, adding that she saw colleagues taking the drug "every day at work".
"I don't see any symptom that would deter me."
F.Dubois--AMWN